Impaired mitochondrial energy production: The basis of pharmacoresistance in epilepsy

Medical Hypotheses

Volumn 77, Issue 4, 2011, Pages 536-540

  Yuen, Alan W C ^a,b   Sander, Josemir W ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EPILEPSY SOCIETY   (United Kingdom)

^c STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTICONVULSIVE AGENT; ARSENIC; CELL NUCLEUS DNA; CREATINE; CREATINE PHOSPHATE; FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; GUANIDINOACETATE METHYLTRANSFERASE; GUANIDINOACETIC ACID; ION CHANNEL; LEAD; MERCURY; MITOCHONDRIAL DNA; N ACETYLASPARTIC ACID; POLYUNSATURATED FATTY ACID; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; THYROID HORMONE; VITAMIN B GROUP;

ALPERS DISEASE; APOPTOSIS; ARTICLE; CALCIUM SIGNALING; CELL FUNCTION; CELL METABOLISM; CELL PROLIFERATION; CELL STRUCTURE; CITRIC ACID CYCLE; CLINICAL EFFECTIVENESS; CORTICAL DYSPLASIA; DEPRESSION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; ENERGY METABOLISM; ENERGY YIELD; ENZYME DEFICIENCY; EPILEPSY; EPILEPTIC FOCUS; EPILEPTOGENESIS; FAMILY HISTORY; FEBRILE CONVULSION; FOLLOW UP; GENE MUTATION; HEME SYNTHESIS; HIPPOCAMPAL SCLEROSIS; HUMAN; INFANTILE SPASM; INTRACTABLE EPILEPSY; KETOGENIC DIET; LEIGH DISEASE; LIFESTYLE; MELAS SYNDROME; MERRF SYNDROME; MICRODIALYSIS; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NEUROCHEMISTRY; NONHUMAN; NUTRITION; OXIDATIVE STRESS; PH; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; PURKINJE CELL; PYRAMIDAL NERVE CELL; RESPIRATORY CHAIN; STEROIDOGENESIS; TEMPORAL LOBE EPILEPSY; TRAUMATIC BRAIN INJURY;

ANTICONVULSANTS; BRAIN; DRUG RESISTANCE; ENERGY METABOLISM; EPILEPSY; HUMANS; MITOCHONDRIA;

ANIMALIA;

EID: 80052619771     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.06.025     Document Type: Article

References (47)

1. Sander J.W. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003, 16(2):165-170.
2. Sander J.W. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993, 34(6):1007-1016.
3. Kwan P., Brodie M.J. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005, 46(2):224-235.
4. Remy S., Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006, 129(Pt 1):18-35.
5. Rogawski M.A., Johnson M.R. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 2008, 8(5):127-130.
6. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342(5):314-319.
7. Williams R. Martin Brodie: epilepsy expertise and whisky wisdom. Lancet Neurol 2009, 8(11):984.
8. Pati S., Alexopoulos A.V. Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies. Cleve Clin J Med 2010, 77(7):457-467.
9. Hitiris N., Mohanraj R., Norrie J., Sills G.J., Brodie M.J. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007, 75(2-3):192-196.
10. Scaglia F. The role of mitochondrial dysfunction in psychiatric disease. Dev Disabil Res Rev 2010, 16(2):136-143.
11. Kudin A.P., Zsurka G., Elger C.E., Kunz W.S. Mitochondrial involvement in temporal lobe epilepsy. Exp Neurol 2009, 218(2):326-332.
12. Kunz W.S., Kudin A.P., Vielhaber S., et al. Mitochondrial complex I deficiency in the epileptic focus of patients with temporal lobe epilepsy. Ann Neurol 2000, 48(5):766-773.
13. Pan J.W., Williamson A., Cavus I., et al. Neurometabolism in human epilepsy. Epilepsia 2008, 49(Suppl. 3):31-41.
14. Leuzzi V. Inborn errors of creatine metabolism and epilepsy: clinical features, diagnosis, and treatment. J Child Neurol 2002, 17(Suppl. 3). 3S89-3S97.
15. Schulze A., Bachert P., Schlemmer H., et al. Lack of creatine in muscle and brain in an adult with GAMT deficiency. Ann Neurol 2003, 53(2):248-251.
16. DeVivo D.C., Leckie M.P., Ferrendelli J.S., McDougal D.B. Chronic ketosis and cerebral metabolism. Ann Neurol 1978, 3(4):331-337.
17. Balietti M., Giorgetti B., Di S.G., Casoli T., et al. A ketogenic diet increases succinic dehydrogenase (SDH) activity and recovers age-related decrease in numeric density of SDH-positive mitochondria in cerebellar Purkinje cells of late-adult rats. Micron 2010, 41(2):143-148.
18. Bough K.J., Wetherington J., Hassel B., et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006, 60(2):223-235.
19. Jarrett S.G., Milder J.B., Liang L.P., Patel M. The ketogenic diet increases mitochondrial glutathione levels. J Neurochem 2008, 106(3):1044-1051.
20. Duchen M.R. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Aspects Med 2004, 25(4):365-451.
21. Bough K.J., Rho J.M. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 2007, 48(1):43-58.
22. Andrews Z.B., Diano S., Horvath T.L. Mitochondrial uncoupling proteins in the CNS: in support of function and survival. Nat Rev Neurosci 2005, 6(11):829-840.
23. Pan J.W., Bebin E.M., Chu W.J., Hetherington H.P. Ketosis and epilepsy: 31P spectroscopic imaging at 4.1 T. Epilepsia 1999, 40(6):703-707.
24. Ackman J.B., Aniksztejn L., Crepel V., et al. Abnormal network activity in a targeted genetic model of human double cortex. J Neurosci 2009, 29(2):313-327.
25. Depeint F., Bruce W.R., Shangari N., Mehta R., O'Brien P.J. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. Chem Biol Interact 2006, 163(1-2):94-112.
26. Depeint F., Bruce W.R., Shangari N., Mehta R., O'Brien P.J. Mitochondrial function and toxicity: role of B vitamins on the one-carbon transfer pathways. Chem Biol Interact 2006, 163(1-2):113-132.
27. Addanki A., Cahill F.D., Sotos J.F. Determination of intramitochondrial pH and intramitochondrial-extramitochondrial pH gradient of isolated heart mitochondria by the use of 5, 5-dimethyl-2, 4-oxazolidinedione. I. Changes during respiration and adenosine triphosphate-dependent transport of Ca++, Mg++, and Zn++. J Biol Chem 1968, 243(9):2337-2348.
28. Gursahani H.I., Schaefer S. Acidification reduces mitochondrial calcium uptake in rat cardiac mitochondria. Am J Physiol Heart Circ Physiol 2004, 287(6):H2659-H2665.
29. Duchen M.R. Mitochondria and calcium: from cell signalling to cell death. J Physiol 2000, 529(Pt 1):57-68.
30. Pizzorno J., Frassetto L.A., Katzinger J. Diet-induced acidosis: is it real and clinically relevant?. Br J Nutr 2010, 103(8):1185-1194.
31. Neustadt J., Pieczenik S.R. Medication-induced mitochondrial damage and disease. Mol Nutr Food Res 2008, 52(7):780-788.
32. Cohen B.H. Pharmacologic effects on mitochondrial function. Dev Disabil Res Rev 2010, 16(2):189-199.
33. Finsterer J., Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 2010, 33(2):138-151.
34. Menshikova E.V., Ritov V.B., Fairfull L., Ferrell R.E., Kelley D.E., Goodpaster B.H. Effects of exercise on mitochondrial content and function in aging human skeletal muscle. J Gerontol A Biol Sci Med Sci 2006, 61(6):534-540.
35. Spina R.J., Chi M.M., Hopkins M.G., Nemeth P.M., Lowry O.H., Holloszy J.O. Mitochondrial enzymes increase in muscle in response to 7-10 days of cycle exercise. J Appl Physiol 1996, 80(6):2250-2254.
36. Little J.P., Safdar A., Wilkin G.P., Tarnopolsky M.A., Gibala M.J. A practical model of low-volume high-intensity interval training induces mitochondrial biogenesis in human skeletal muscle: potential mechanisms. J Physiol 2010, 588(Pt 6):1011-1022.
37. Holloszy J.O. Regulation by exercise of skeletal muscle content of mitochondria and GLUT4. J Physiol Pharmacol 2008, 59(Suppl 7):5-18.
38. Weitzel J.M., Iwen K.A., Seitz H.J. Regulation of mitochondrial biogenesis by thyroid hormone. Exp Physiol 2003, 88(1):121-128.
39. Menzies K.J., Robinson B.H., Hood D.A. Effect of thyroid hormone on mitochondrial properties and oxidative stress in cells from patients with mtDNA defects. Am J Physiol Cell Physiol 2009, 296(2):C355-C362.
40. Wilms L., Larsen J., Pedersen P.L., Kvetny J. Evidence of mitochondrial dysfunction in obese adolescents. Acta Paediatr 2010, 99(6):906-911.
41. Parra D., Gonzalez A., Mugueta C., Martinez A., Monreal I. Laboratory approach to mitochondrial diseases. J Physiol Biochem 2001, 57(3):267-284.
42. Myhill S., Booth N.E., Laren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009, 2(1):1-16.
43. Hetherington H.P., Pan J.W., Spencer D.D. 1H and 31P spectroscopy and bioenergetics in the lateralization of seizures in temporal lobe epilepsy. J Magn Reson Imaging 2002, 16(4):477-483.
44. Bates T.E., Strangward M., Keelan J., Davey G.P., Munro P.M., Clark J.B. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 1996, 7(8):1397-1400.
45. Rango M., Bozzali M., Prelle A., Scarlato G., Bresolin N. Brain activation in normal subjects and in patients affected by mitochondrial disease without clinical central nervous system involvement: a phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 2001, 21(1):85-91.
46. Lei H., Ugurbil K., Chen W. Measurement of unidirectional Pi to ATP flux in human visual cortex at 7 T by using in vivo 31P magnetic resonance spectroscopy. Proc Natl Acad Sci USA 2003, 100(24):14409-14414.
47. Chen W., Zhu X.H., Adriany G., Ugurbil K. Increase of creatine kinase activity in the visual cortex of human brain during visual stimulation: a 31P magnetization transfer study. Magn Reson Med 1997, 38(4):551-557.